FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2167432895> ?p ?o ?g. }

• W2167432895 endingPage "1749" @default.
• W2167432895 startingPage "1742" @default.
• W2167432895 abstract "Background: Clinical application of platelet-rich plasma (PRP) in the realm of orthopaedic sports medicine has yielded variable results. Differences in separation methods and variability of the individual may contribute to these variable results. Purpose: To compare the effects of different PRP separation methods on human bone, muscle, and tendon cells in an in vitro model. Study Design: Controlled laboratory study. Methods: Blood collected from 8 participants (mean ± SD age 31.6 ± 10.9 years) was used to obtain PRP preparations. Three different PRP separation methods were used: a single-spin process yielding a lower platelet concentration (PRP LP ), a single-spin process yielding high platelet and white blood cell concentrations (PRP HP ), and a double-spin that produces a higher platelet concentration and lower white blood cell concentration (PRP DS ). Human bone, muscle, and tendon cells obtained from discarded tissue samples during shoulder surgery were placed into culture and treated with the 3 PRP preparations, control media (2% fetal bovine serum [FBS] and 10% FBS), and native blood. Radioactive thymidine assays were obtained to examine cell proliferation, and testing with enzyme-linked immunosorbent assay was used to determine growth factor concentrations. Results: Addition of PRP LP to osteocytes, myocytes, and tenocytes significantly increased cell proliferation ( P ≤ .05) compared with the controls. Adding PRP DS to osteoblasts and tenocytes increased cell proliferation significantly ( P ≤ .05), but no significance was shown for its addition to myocytes. The addition of PRP HP significantly increased cell proliferation compared with the controls only when added to tenocytes ( P ≤ .05). Osteoblasts: Proliferation was significantly increased by addition of PRP LP compared with all controls (2% FBS, 10% FBS, native blood) ( P ≤ .05). Addition of PRP DS led to significantly increased proliferation compared with all controls, native blood, and PRP HP ( P ≤ .05). Proliferation was significantly less when PRP HP was added compared with PRP DS ( P ≤ .05). Myocytes: Proliferation was significantly increased by addition of PRP LP compared with native blood ( P ≤ .05). Adding PRP HP or PRP DS to myocytes showed no significant increase in proliferation compared with the controls or the other separations. Tenocytes: Proliferation was significantly increased by addition of PRP LP compared with all controls (2% FBS, 10% FBS, native blood) ( P ≤ .05). Addition of PRP DS showed a significant increase compared with the controls and native blood. For tenocytes, there was a significant increase ( P ≤ .05) seen when PRP HP was added compared with the controls and native blood but not compared with the other separations. Conclusion: The primary findings of this study suggest the application of different PRP separations may result in a potential beneficial effect on the clinically relevant target cells in vitro. However, it is unclear which platelet concentration or PRP preparation may be optimal for the treatment of various cell types. In addition, a “more is better” theory for the use of higher platelet concentrations cannot be supported. This study was not intended to prove efficacy but to provide a platform for future research to be built upon. Clinical Relevance: The utilization of different PRP separations may result in a potentially beneficial effect on the clinically relevant target cells in vitro, but it is unclear which platelet concentration or PRP preparation may be optimal for the treatment of various cell types." @default.
• W2167432895 created "2016-06-24" @default.
• W2167432895 creator A5004690375 @default.
• W2167432895 creator A5032913544 @default.
• W2167432895 creator A5037043161 @default.
• W2167432895 creator A5042389009 @default.
• W2167432895 creator A5042732440 @default.
• W2167432895 creator A5056969401 @default.
• W2167432895 creator A5059869706 @default.
• W2167432895 creator A5062434468 @default.
• W2167432895 creator A5072458580 @default.
• W2167432895 creator A5079427685 @default.
• W2167432895 date "2012-07-16" @default.
• W2167432895 modified "2023-10-17" @default.
• W2167432895 title "The Positive Effects of Different Platelet-Rich Plasma Methods on Human Muscle, Bone, and Tendon Cells" @default.
• W2167432895 cites W1967602239 @default.
• W2167432895 cites W1971397149 @default.
• W2167432895 cites W1972292486 @default.
• W2167432895 cites W1999615716 @default.
• W2167432895 cites W2001732854 @default.
• W2167432895 cites W2008946070 @default.
• W2167432895 cites W2011468880 @default.
• W2167432895 cites W2013518981 @default.
• W2167432895 cites W2015317482 @default.
• W2167432895 cites W2022450902 @default.
• W2167432895 cites W2023239442 @default.
• W2167432895 cites W2027383136 @default.
• W2167432895 cites W2030322516 @default.
• W2167432895 cites W2033870370 @default.
• W2167432895 cites W2037290021 @default.
• W2167432895 cites W2068953235 @default.
• W2167432895 cites W2082547313 @default.
• W2167432895 cites W2083726090 @default.
• W2167432895 cites W2084041307 @default.
• W2167432895 cites W2088986145 @default.
• W2167432895 cites W2097403847 @default.
• W2167432895 cites W2100663133 @default.
• W2167432895 cites W2107816883 @default.
• W2167432895 cites W2114425646 @default.
• W2167432895 cites W2121620043 @default.
• W2167432895 cites W2122366747 @default.
• W2167432895 cites W2131480053 @default.
• W2167432895 cites W2144346647 @default.
• W2167432895 cites W2158175963 @default.
• W2167432895 cites W2163206176 @default.
• W2167432895 cites W2168945706 @default.
• W2167432895 cites W2187510678 @default.
• W2167432895 doi "https://doi.org/10.1177/0363546512452713" @default.
• W2167432895 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22802273" @default.
• W2167432895 hasPublicationYear "2012" @default.
• W2167432895 type Work @default.
• W2167432895 sameAs 2167432895 @default.
• W2167432895 citedByCount "161" @default.
• W2167432895 countsByYear W21674328952012 @default.
• W2167432895 countsByYear W21674328952013 @default.
• W2167432895 countsByYear W21674328952014 @default.
• W2167432895 countsByYear W21674328952015 @default.
• W2167432895 countsByYear W21674328952016 @default.
• W2167432895 countsByYear W21674328952017 @default.
• W2167432895 countsByYear W21674328952018 @default.
• W2167432895 countsByYear W21674328952019 @default.
• W2167432895 countsByYear W21674328952020 @default.
• W2167432895 countsByYear W21674328952021 @default.
• W2167432895 countsByYear W21674328952022 @default.
• W2167432895 countsByYear W21674328952023 @default.
• W2167432895 crossrefType "journal-article" @default.
• W2167432895 hasAuthorship W2167432895A5004690375 @default.
• W2167432895 hasAuthorship W2167432895A5032913544 @default.
• W2167432895 hasAuthorship W2167432895A5037043161 @default.
• W2167432895 hasAuthorship W2167432895A5042389009 @default.
• W2167432895 hasAuthorship W2167432895A5042732440 @default.
• W2167432895 hasAuthorship W2167432895A5056969401 @default.
• W2167432895 hasAuthorship W2167432895A5059869706 @default.
• W2167432895 hasAuthorship W2167432895A5062434468 @default.
• W2167432895 hasAuthorship W2167432895A5072458580 @default.
• W2167432895 hasAuthorship W2167432895A5079427685 @default.
• W2167432895 hasConcept C126322002 @default.
• W2167432895 hasConcept C134018914 @default.
• W2167432895 hasConcept C142724271 @default.
• W2167432895 hasConcept C1491633281 @default.
• W2167432895 hasConcept C16685009 @default.
• W2167432895 hasConcept C185592680 @default.
• W2167432895 hasConcept C203014093 @default.
• W2167432895 hasConcept C207200792 @default.
• W2167432895 hasConcept C2778488018 @default.
• W2167432895 hasConcept C2779404806 @default.
• W2167432895 hasConcept C2780076745 @default.
• W2167432895 hasConcept C2780105995 @default.
• W2167432895 hasConcept C55493867 @default.
• W2167432895 hasConcept C62112901 @default.
• W2167432895 hasConcept C71924100 @default.
• W2167432895 hasConcept C89560881 @default.
• W2167432895 hasConceptScore W2167432895C126322002 @default.
• W2167432895 hasConceptScore W2167432895C134018914 @default.
• W2167432895 hasConceptScore W2167432895C142724271 @default.
• W2167432895 hasConceptScore W2167432895C1491633281 @default.
• W2167432895 hasConceptScore W2167432895C16685009 @default.
• W2167432895 hasConceptScore W2167432895C185592680 @default.

• next